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Summary We previously demonstrated in a group of patients with perennial allergic
rhinitis alone, impairment of spirometric parameters and high percentage of
bronchial hyperreactivity (BHR). Thus, the present study aimed at evaluating a group
of subjects suffering from seasonal allergic rhinitis alone to investigate the presence
of spirometric impairment and BHR both during and outside the pollen season.
Methods: One-hundred rhinitics sensitized to pollen allergens only were evaluated
during and outside the pollen season. Spirometry and methacholine bronchial
challenge were performed.
Results: Four rhinitics showed impaired values of FEV1 without referred symptoms
of asthma during the pollen season. FEF 25–75 values were impaired in 17 rhinitics
during the pollen season and in 11 rhinitics outside the pollen season (Po0:05). Fifty-
four patients showed positive methacholine bronchial challenge both during and
outside the pollen season. PD20/FEV1 methacholine was lower during the pollen
season than outside (Po0.05). In BHR positive patients, reduced values of FVC
(Po0:05), FEV1 (Po0:05), and FEF 25–75 (Po0:01) were significantly demonstrated
in comparison with BHR negative rhinitics. There was a relationship between BHR
degree and FEF 25–75 values only during the pollen season (Po0:001).
Conclusions: This study evidences that an impairment of spirometric parameters
may be observed also in patients with seasonal allergic rhinitis alone during the
pollen season. A high percentage of these patients had BHR. A close relationship
between upper and lower airways is confirmed also in the model of pollen allergy.
Thus, a careful evaluation of lower airways should be performed also in those
patients with seasonal allergic rhinitis alone.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Allergic rhinitis is characterized by an inflammatory
response of the nose induced by an IgE-mediated
reaction following allergen exposure.1
Several studies demonstrated a close association
between allergic rhinitis and asthma.2–5 In addition,
ARTICLE IN PRESS
KEYWORDS
Seasonal allergic rhinitis;
Bronchial hyperreactivity;
Methacholine challenge;
FEF 25–75
*Corresponding author. Tel.: þ 39-10-555-2124; fax: þ 39-10-
555-6682.
E-mail address: gio.cip@libero.it (G. Ciprandi).
0954-6111/$ - see front matter & 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.rmed.2004.02.021
Respiratory Medicine (2004) 98, 826–831
we reported that 77% of conscripts with respiratory
allergy suffered from asthma associated with
allergic rhinitis.6
Allergic rhinitis has been demonstrated to be a
strong risk factor for the onset of asthma in adults.7
Asthma is characterized by a reversible airflow
obstruction and forced expiratory volume/1 s
(FEV1) is considered the main parameter to
evaluate bronchial obstruction.8 Nevertheless,
there is increasing interest to consider the involve-
ment of small airways in the pathogenesis of
asthma.9 Even though, there is no direct parameter
able of assessing small airways, it has been assumed
that the forced expiratory flow at the 25% and 75%
of the pulmonary volume (FEF 25–75) might be
considered as a measure of the caliber concerning
distal airways.10 Particularly, subjects with mild
asthma and normal FEV1 may show impaired FEF
25–75 only.11
On the other hand, bronchial hyperreactivity
(BHR) is a paramount feature of asthma. Moreover,
BHR may be observed in a proportion of rhinitics.12
In this regard, it has been hypothesized that a
positive bronchial challenge to methacholine could
be considered as predictive for those rhinitics
would progress to develop asthma.13 BHR was
reported both in patients with perennial allergic
rhinitis and in subjects with seasonal allergic
rhinitis.14 In addition, a seasonal variability in
BHR was described in subjects sensitized to
pollens.15 Very recently, we demonstrated that
48% of patients with perennial allergic rhinitis
alone showed reduced FEF 25–75 values.16 More-
over, 72% of patients showed positive methacholine
challenge, and there was a significant relationship
between BHR degree and FEV1 (Po0.05) and FEF
25–75 (Po0.01) values.16
On the basis of these considerations, we aimed at
evaluating a group of patients with seasonal
allergic rhinitis alone to investigate the presence
of BHR and spirometric abnormalities both during
and outside the pollen season.
Materials and methods
Study design
The study was performed during (when patients
were symptomatic) and outside the pollen season
(when patients were symptomless). To evaluate
spirometric abnormalities and the presence of BHR
in patients with pure seasonal rhinitis, we included
subjects with allergic rhinitis due to pollen aller-
gens only. We excluded all the subjects who met
the following exclusion criteria: asthma symptoms,
including cough, wheezing, dyspnoea, and short-
ness of breathing, allergy to perennial allergens,
acute upper respiratory infections and use of nasal
or oral corticosteroids, and antihistamines within
the previous 4 weeks.
The study was approved by the Institutional
Review Board and an informed consent was
obtained from patients.
Subjects
One-hundred rhinitic patients were prospectively
and consecutively evaluated, all males, age
23.774.9 years. All of them were Navy soldiers
who referred to Navy Hospital for periodic fitness
visit. All of them were evaluated performing both
spirometry and methacholine bronchial challenge
during the pollen season, i.e. in the spring.
Successively, all of them were re-evaluated outside
the pollen season, i.e. in the winter, season without
pollens in our geographic area.6
A detailed clinical history and a complete
physical examination, including allergy evaluation,
were performed. The patients were included in the
study on the basis of a clinical history of seasonal
allergic rhinitis. All patients were sensitized to
pollens only (i.e. Parietaria officinalis, grasses,
olive tree, birch, and hazel). The diagnosis of
seasonal allergic rhinitis was made on the basis of a
history of nasal symptoms and positive skin prick
test for pollens as described elsewhere.6 None of
the patients was a previous or a current smoker.
Skin prick test
It was performed, as stated by the Italian Society of
Allergy and Clinical Immunology.17 The panel
consisted of: house dust mites (Dermatophagoides
farinae and pteronyssinus), cat, dog, grasses mix,
Compositae mix, Parietaria officinalis, birch, ha-
zel, olive tree, Alternaria Tenuis, Cladosporium,
Aspergilli mix (Stallergenes, Milan, Italy).
Spirometry
It was performed by using a computer-assisted
spirometer (COSMED, Eurasem, Italy), with optoe-
lectronic whirl flow meter. Spirometry is performed
as stated by ERS18, using the European Community
for Steel and coal (ECSC) reference equations and
C.E.C.A.
If an airway obstruction was present as detected
by FEV1 values less than 80% of the predicted, a
test of bronchodilatation was performed using a
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salbutamol metered dose of 200mcg. Reversibility
was considered if an increase of at least 12% of FEV1
from baseline was achieved, according to interna-
tional guidelines19.
Methacholine bronchial challenge
It was performed to evaluate BHR only if basal FEV1
was equal or more than 80% of predicted. Aerosol is
delivered using a dosimetric computerized supply
(MEFAR MB3, Marcos, Italy). Subjects inhaled
increasing doses of methacholine, starting from
34 mg/ml. The scheduled doses consisted of the
following: 34, 68, 68, 170, 170, 340, 170, 340,
170 mg/ml as previously reported.6,16
The test was interrupted when FEV1 value was
reduced by more or equal than 20% or a maximal
cumulative dose of 1590 mg/ml was achieved. The
threshold dose causing a 20% fall of FEV1 (PD20) was
calculated.
Degree of BHR
Four arbitrary classes of BHR were considered: very
mild¼ PD204400 mg/ml, mild¼ PD20 ranging from
201 to 400 mg/ml, moderate¼ PD20 ranging from
200 to 101 mg/ml, and severe¼ PD20 o100 mg/ml
as previously reported.6,16
Statistical analysis
Statistical analysis was performed using w2 test,
calculating confidential limits of the relative risk at
95%. Differences were considered significant if P
values were o0.05. Data are presented as means.
Results
All rhinitics were consecutive subjects meeting the
inclusion and exclusion criteria and agreeing to join
the study.
No adverse event was reported during the study.
During pollen season findings
Spirometry: Four patients showed a FEV1 value less
than 80% of the predicted (Fig. 1A). It has to be
mentioned that all of them were completely
symptomless for complaints concerning lower air-
ways. A bronchial reversibility was achieved in all
subjects.
Then, we evaluated the distribution of the
patients considering FVC values (Fig. 1B), and FEF
25–75 values (Fig. 1C). Eight patients showed
impaired FVC values. Seventeen patients showed
reduced FEF 25–75 values.
Methacholine bronchial challenge: It was per-
formed in 96 rhinitics. Fifty-four rhinitics showed a
positive methacholine challenge. On the basis of
BHR degree, we subdivided the methacholine
positive patients in 4 groups: very mild, mild,
moderate, and severe. Fourteen patients had a
very mild degree of BHR, 16 had a mild degree, 16
had a moderate degree, and 8 a severe degree (Fig.
1D).
Then, we analyzed subjects subdividing them in
two groups: patients with BHR (BHR positive group)
and patients without BHR (BHR negative group).
FEF 25–75 values were reduced in 10 subjects of
BHR positive group and in seven subjects of BHR
negative group.
We considered the three spirometric parameters
related with BHR degree (Fig. 2A). A significant
difference was observed for FEF 25–75 only
(Po0.01) considering BHR severity.
Outside pollen season findings
Spirometry: All subject showed normal FEV1 values
(Fig. 1A). Five subjects showed reduced FVC values
(Fig. 1B) and 11 subjects showed impaired FEF 25–
75 values (Fig. 1C).
Methacholine bronchial challenge: It was per-
formed in all rhinitics (1 0 0). Fifty-four rhinitics
showed a positive methacholine challenge. Nine-
teen patients had a very mild degree of BHR, 11 had
a mild degree, 13 had a moderate degree, and 11 a
severe degree (Fig. 1D).
FEF 25–75 values were reduced in seven subjects
of BHR positive group and in four subjects of BHR
negative group.
No significant differences were observed for the
3 spirometric parameters considering BHR severity
(Fig. 2B).
During versus outside pollen season findings
Spirometry: There was a significant difference
concerning the number of rhinitics with abnormal
FEV1 values: 4 versus 0 (Po0.001).
Concerning FEF 25–75 values, there was a
significant difference between the two time of
observation: 17 patients with FEF 25–75o80% of
predicted during the pollen season in comparison
with 11 patients evaluated outside the pollen
season (Po0.05).
Methacholine bronchial challenge: The mean
methacholine PD20/FEV1 was 3527331mg/ml during
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the pollen season, whereas it was 4487427mg/ml
outside the pollen season (Po0.05).
Concerning the BHR positive patients, there is a
different impairment of FEF 25–75 values compar-
ing during and outside pollen season findings
(Po0.05). Equally for BHR negative patients, a
different impairment of FEF 25–75 values is
detectable between the two period of observation
(Po0.05).
A significant relationship between BHR grade and
FEF 25–75 values is detectable in BHR positive
patients during the pollen season only (Fig. 2A).
Discussion
Allergic rhinitis and asthma should be considered as
a single syndrome involving two parts of the
respiratory tract.20 Moreover, it is evident that
these two disorders affect each other. The patho-
physiology of allergic rhinitis is similar to that of
asthma and their responses to pharmacological and
specific immunological interventions are compar-
able.21 Epidemiological evidence supports the close
link between allergic rhinitis and asthma and cross-
sectional population surveys suggest that allergic
rhinitis is a major risk factor for asthma develop-
ment.21
Allergic rhinitis may contribute to worsen asthma
through different pathophysiologic mechanisms:
post-nasal drip, nasal-bronchial reflex, oral breath-
ing, and systemic allergic inflammation.19
Allergic rhinitics frequently present a non-spe-
cific BHR even in absence of asthmatic symptoms.
In these subjects with normal FEV1 values, BHR may
be envisaged as a marker of susceptibility to
develop asthma.
On the other hand, in mild asthmatics during
intercritical periods lung function may be normal
concerning FEV1 values.
22 Moreover, asthma is a
chronic inflammatory disease of airways and using
other parameters it has been demonstrated a
persistence of inflammation, also in absence of
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Figure 1 Quadrant A percentage distribution of FEV1 values (as % of predicted) during and outside the pollen season;
quadrant B percentage distribution of FVC values (as % of predicted) during and outside the pollen season; quadrant C
percentage distribution of FEF 25–75 values (as % of predicted) during and outside the pollen season; quadrant D
percentage distribution of BHR grade during and outside the pollen season.
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symptoms, mainly involving smaller airways.23 In
these cases, abnormal FEF 25–75 values may be
observed: it has been reported that FEF 25–75 may
be reduced in asthmatics with normal FEV1 and FVC
values.11 It has been suggested that FEF 25–75
might be considered a marker of small airways
impairment in mild asthmatics with normal FVC
values.10
Very recently, we demonstrated some interesting
findings in a group of 100 patients with perennial
allergic rhinitis alone.16 Five patients showed
impaired FEV1 values (o80% of predicted), without
any perceived lower respiratory symptoms and 48
patients showed reduced FEF 25–75 values.16
Moreover, 72 patients showed positive methacho-
line challenge, and there was a significant relation-
ship between BHR degree and FEV1 and FEF 25–75
values.16 Thus, we aimed at investigating a large
group of patients with seasonal allergic rhinitis
both during and outside the pollen season to
evaluate the influence of the natural allergen
exposure on spirometry and BHR.
The present findings suggest some considerations
concerning the link between upper and lower
airways and the variations of respiratory para-
meters consequent on allergen exposure.
Firstly, evaluating a large cohort of subjects with
seasonal allergic rhinitis alone, it is possible to
single out some subjects with overt bronchial
obstruction, as documented by impaired FEV1
values, during the pollen season. These patients
may be considered as ‘‘poor perceiver’’ of their
lower respiratory symptoms. In fact, all of them
had a normal life playing different sports without
trouble. In addition, they never felt lower respira-
tory symptoms nor diagnosis of asthma has been
made. In addition, it has to be highlighted that no
subject showed overt bronchial obstruction outside
the pollen season. This issue confirms the close
relationship between pollen exposure and asthma
appearance in those patients.
Secondly, most of our rhinitics (54%) showed BHR.
This finding is not surprising if compared with
literature analysis. The exposure to allergens is
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Figure 2 Quadrant A percentage distribution of mean values of FVC, FEV1, and FEF 25–75 in comparison with BHR
grade during the pollen season; quadrant B percentage distribution of mean values of FVC, FEV1, and FEF 25–75 in
comparison with BHR grade outside the pollen season.
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characterized by nasal inflammation as previously
described by ourselves.24 This concept may be
consistent with a consequent bronchial inflamma-
tion.25 It is noteworthy that BHR was asymptomatic
in all our rhinitics. Even though the number of BHR
positive patients remains unchanged outside sea-
son, the PD20/FEV1 methacholine significantly
increased outside the pollen season. This point
further on remarks the close connection between
BHR and allergen exposure.
Thirdly, considering the evaluation of FEF 25–75
parameter we demonstrated that some rhinitics17
show an initial level of bronchial obstruction during
the pollen season. It is noteworthy that this
percentage diminishes outside the pollen season,
but does not disappear: 11 patients continue to
present this impairment. This issue is consistent
with the concept that chronic bronchial inflamma-
tion as well as BHR may persist also in absence of
allergen exposure.
Fourthly, there is a relationship between degree
of BHR and FEF 25–75 impairment, mainly during
the pollen season and in BHR positive patients. That
finding underlines the relationship between BHR
and airway caliber in patients with airway inflam-
mation.
These data, taken together, partially confirm
previous results observed in those patients with
perennial allergic rhinitis.16 Patients with perennial
allergic rhinitis, compared with patients with
seasonal allergic rhinitis, more obviously show an
association with asthma, the impairment of FEF 25–
75, the BHR, and the relationship between BHR
grade and spirometric abnormalities.
Anyway, our data suggest that a new diagnostic
approach should be carried out also in those
patients with seasonal allergic rhinitis.
Thus, rhinitics should be carefully followed up to
evaluate the possible onset of asthma.
In conclusion, our study highlights the frequent
coexistence of bronchial impairment in those
patients with seasonal allergic rhinitis alone and
supports the strong link between upper and lower
airways.
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